Community post
Locus Biosciences signed a $144 million contract with BARDA to support phase II and III clinical trials of LBP-EC01, Locus' CRISPR phage (crPhage™) product.
Topics
Links
| Source | Capsid & Tail #95 |
|---|---|
| Original post | Original post |
Locus Biosciences signed a $144 million contract with BARDA to support phase II and III clinical trials of LBP-EC01, Locus' CRISPR phage (crPhage™) product.
| Source | Capsid & Tail #95 |
|---|---|
| Original post | Original post |